Vanda plans FDA sNDA filing for Hetlioz in delayed sleep-wake phase disorder
Bitget2026/09/29 22:46- Vanda reported positive Phase III results for HETLIOZ (tasimelteon) in Delayed Sleep-Wake Phase Disorder.
- Plans to meet FDA, file a supplemental NDA seeking a new indication for DSWPD.
- Trial met primary endpoint: sleep onset shifted 37.1 minutes earlier versus placebo (p=0.022).
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Fixed income stalls and stocks take the crown! Wall Street’s big banks report an epic “song of ice and fire” season, marking the darkest hour for a generation of bond traders
As Wall Street's fixed income division came under pressure in the third quarter, its equities division competitors seized this rare opportunity, overshadowing their peers in the fixed income sector.
Rio Tinto on track to release $5 billion in capital after Q3 iron ore sales top estimates
Glencore shares to start trading in Australia as miner hopes to boost valuation
How will the market perform during the remainder of 2026?
Crypto prices
More
